BeStock  
Stocks › ABCL

AbCellera Biologics ABCL

US equityMarket cap rank #2192AI medical concept stocks
$13.78 +$0.04 (+0.29%)
Market closed · Oct 6, 1:10 am ET · Last extended-hours $13.86 +0.56%
Open$13.72
Prev close$13.74
Day range$13.21 – $13.88
Volume4.08M
Market cap$4.47B
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.

Community Sentiment on ABCL

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

ABCL at a glance

ABCL is priced at $13.78 right now, up 0.29% on the session. That puts its market value at $4.47B, 2192nd largest among the 3132 stocks we cover.

The 52-week range is $2.75 to $15.02. Today's price is about 90% of the way from the low to the high. Holders are ahead 134.8% over twelve months, and up 79.2% across the last three months.

On the chart it holds above both the 50-day ($10.70) and 200-day ($6.03) moving averages; RSI is 64, and the last 30 sessions moved at roughly 78% annualized volatility.

9 analysts follow the stock and the average call is "buy". The mean target, $16.63, sits 20.7% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

BeStock Grade

B
BeStock Grade

Composite of 2 factors below, ranked against the 3132 U.S. stocks BeStock covers.

B
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

9 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

ABCL is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$16.63+20.7% vs. current price
Consensus ratingBuy9 analysts covering
Morningstar fair value$15.12Price is below fair value

Wall Street’s average 12-month target is $16.63, 20.7% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $15.12, so shares trade 8.9% below that estimate.

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
+0.3%
1 week
-1.0%
1 month
+19.1%
3 months
+79.2%
6 months
+306.5%
Year to date
+302.9%
1 year
+134.8%
Day range
$13.21$13.88
52-week range
$2.75$15.02

Technical signals

Full technicals →
Trend readStrong uptrend

7 bullish · 0 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average+9.7%Bullish
Price vs 50-day average+28.8%Bullish
Price vs 200-day average+128.4%Bullish
50-day vs 200-day50d above 200dBullish
RSI (14)63.9Bullish
MACD (12,26,9)0.93Bullish
Bollinger band position74%Bullish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Key statistics

Bid / Ask$13.76 / $13.86
Average price today$13.63
Volume4.08MAvg (90d) 7.02M
Turnover$55.55M
Turnover rate1.85%of shares outstanding
Volume ratio0.61vs. recent average pace
Day amplitude4.88%
Market cap$4.47B
Float market cap$3.04B
Shares outstanding220.93M
EPS (TTM)-$0.49
P/B4.98
Book value / share$2.77
Earnings yield-0.20%
Net profit (TTM)-$158.78M
Net assets$895.99M
30-day volatility78.4%annualized
Avg daily range (ATR)5.83%of price, 14 days
Max drawdown (1y)-54.9%-7.0% from 1y peak

Quote as of Oct 6, 2026 1:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.

How ABCL ranks on BeStock

Market value#2192 of 3132
Closeness to 52-week high#562 of 3127
Dollar volume today#1358 of 3132

Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

ABCL stock: common questions

How is AbCellera Biologics stock doing today?

$13.78 is the latest print for ABCL, a move of +0.29% against yesterday's close of $13.74. Today's low and high so far: $13.21 and $13.88.

What is ABCL worth in total?

Equity value comes to $4.47B at the current price. By that measure it is number 2192 of the 3132 names in our coverage.

How far is ABCL from its yearly high?

The year's floor is $2.75 and the ceiling $15.02. Shares are 8.2% away from that ceiling.

Are there dividends on AbCellera Biologics shares?

Our data shows no dividend paid by AbCellera Biologics over the trailing twelve months.

What is the analyst view on AbCellera Biologics?

Of 9 analysts, 89% say buy, 11% hold and 0% sell. Price targets average $16.63, with the most cautious at $9.00 and the most optimistic at $30.00.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on ABCL.

Leave a comment

Scroll to Top